Logo
Login
$SER
$1.67 -$0.04 (2.34%) Close

Company Executives

$SER Management Team

Dr. Balkrishan Gill

Executive Chairman of the Board

Age 61
Compensation $3.039M USD
Sex Male

Mr. Steven Ledger

Chief Executive Officer

Director

Age 65
Compensation $3.704M USD
Sex Male

Mr. Gregory Curhan

Chief Financial Officer

Age 63
Compensation $1.700M USD
Sex Male

Dr. Randall Moreadith

Chief Development Officer

Age 71
Compensation $433.9K USD
Sex Male

Dr. Srini Tenjarla

Senior Vice President - CMC and Formulation

Age 63
Compensation $1.781M USD
Sex Male

Board of Directors

From the proxy statement filed Apr 27, 2026
Directors
7
serving now
Independent
Not stated
the proxy does not say
Average tenure
2.7 years
from year joined
CEO also chairs the board
No
Gregory H. Bailey, M.D. and Balkrishan “Simba” Gill
Director Age On board Independent Committees Other public boards 2025 pay Source
Gregory H. Bailey, M.D.
Board chair
 70 2018
8 years
 Not stated
Compensation
BioHaven Ltd., Manx Financial Group, plc, SalvaRx Group, plc $82,616
Richard Marshall, CBE, M.D., Ph.D.
59 2024
2 years
 Not stated
Nominating and Corporate Governance
None stated $82,616
Jay Venkatesan, M.D.
54 2025
1 year
 Not stated
Audit Nominating and Corporate Governance · Chair
Elicio Therapeutics, Inc. $222,160
Balkrishan “Simba” Gill
Board chair
 62 2024
2 years
 Not stated None stated Foghorn Therapeutics Not stated
Stephen Brannan, M.D.
69 2025
1 year
 Not stated
Audit Compensation
None stated $255,375
Steve Ledger
CEO
 66 2022
4 years
 Not stated None stated None stated Paid as CEO
Karen J. Wilson
63 2025
1 year
 Not stated
Audit · Chair Compensation · Chair Nominating and Corporate Governance
Connect Biopharma Holdings Limited, Elicio Therapeutics, Inc. $240,105

Each director opens the passage of the proxy that names them. "Not stated" means the proxy does not say; it never means "no". Pay is the proxy's Director Compensation table; the CEO is paid as an executive.

Related-party transactions

4 disclosed in the proxy filed Apr 27, 2026
Gregory H. Bailey, M.D.
a member of the Company’s Board of Directors
Purchase price of $2.25 per share
March 2026

Led the March 2026 private placement of common stock and pre-funded warrants at $2.25 per share, with accompanying redeemable warrants.

With the Company Open in proxy
Gregory H. Bailey, M.D.
a member of the Company’s Board of Directors
Up to $20 million
September 9, 2025

Unsecured convertible note under which Dr. Bailey agreed to make available borrowings to the Company.

With the Company Open in proxy
Gregory H. Bailey, M.D.
investor in the Series A Convertible Preferred Stock private placement
Approximately $5 million
April 8, 2025

Purchased shares of Series A Convertible Preferred Stock in a private placement at $5.18 per share.

With the Company Open in proxy
Dr. Venkatesan
investor in the Series A Convertible Preferred Stock private placement
Amount not stated
April 8, 2025

Participated as an investor in the April 2025 private placement of Series A Convertible Preferred Stock.

With the Company Open in proxy

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support
View Pricing Plans